The Latest Cardiac and Vascular News
WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its financial results for the quarter ended September […]
Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare Dedicated Investors Companies to Hold Conference Call on September 24th at 8:30AM EDT WALTHAM, Mass. and NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) — Proteon […]
WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its financial results for the quarter ended June 30, 2019, and recent […]
WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended March 31, 2019, and recent events. Recent Events PATENCY-2 Trial Misses Statistical […]
WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its plans to explore a range of strategic options to enhance shareholder value. Having missed statistical significance on both […]
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the year ended December 31, 2018, and recent business highlights. “We are looking forward to […]
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March […]
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended September 30, 2018, and recent business highlights. “We made excellent progress in […]
